Trump’s Watered-Down Medicare Drug Pricing Rule Saves Billions Less Than Initial Proposal

Trump’s watered-down Medicare drug pricing rule saves billions less than initial proposal

The Trump administration just published a final rule aimed at Medicare drug prices for office-administered drugs. The catch: it now applies to only four companies instead of the many it was meant to cover.

The rule is part of a broader plan called the most-favored nation (MFN) pricing approach. Under that plan, Global is one of two mandatory pilot programs. The other, GUARD, remains in proposed stage. Companies that signed voluntary MFN deals with the administration for Medicaid recipients are exempt from Global.

Which Four Companies Are Subject To Global

The final rule does not name which four companies are subject to Global. That means the public cannot see which firms will face the new pricing requirements and which will not. The exemption for companies that already agreed to voluntary deals with the administration leaves the rule’s reach far narrower than it started.

What The Rule Excludes

The rule also excludes drugs for rare diseases. But there is a loophole: drugs treating both rare diseases and non-rare conditions will not receive the exclusion. That means some patients could still end up paying more than expected.

The Savings Collapse

Medicare actuaries estimate the savings dropped from nearly $12 billion in the proposed rule to $440 million.

Thomas Hwang, a Harvard researcher studying Global’s potential savings, said the reduction matches his estimate.

How The Two Pilots Compare

Global and GUARD are both part of the same MFN pricing plan. They differ in one key way:

1. Global is mandatory — the administration has already put it into effect as a final rule.
2. GUARD is still in proposed stage — it has not yet been finalized.

The Narrow Reach

The rule applies to only four companies. That is a dramatic shrinkage from the administration’s original intent. The MFN approach was meant to force drugmakers to charge Medicare prices closer to those abroad.

Instead, the final rule targets a tiny fraction of the market.

The Public Cannot See The Deals

Because the rule does not name the four companies, the public cannot see which firms are being asked to change their prices and which are not. That lack of transparency matters for anyone trying to understand how the rule will actually work.

What Happens Next

GUARD remains in proposed stage. Global is the only mandatory pilot program currently moving forward.

The administration’s own estimates show the rule’s savings collapsed. The question now is whether that collapse will hold.

The Bottom Line

The administration exempted companies that already agreed to voluntary MFN deals for Medicaid recipients, shrinking the rule’s reach to just four firms. That arrangement narrows the rule’s impact significantly.

The savings are now a fraction of what the administration promised. The rule’s reach is a fraction of what it was meant to be.

That is the reality of this rule.

Where the paper stands

The paper backs smaller government and is against agencies writing their own authority, especially when those agencies narrow the scope of rules aimed at drug prices. Here, an administration that promised a sweeping Medicare price-cutting rule has instead produced one that applies to only four companies, with exemptions for firms that already made separate deals for Medicaid. The savings have collapsed from nearly $12 billion to $440 million. The public cannot even see which four companies are involved.

The rule’s narrowed reach comes from within the administration itself. By exempting companies that already agreed to voluntary Medicaid deals, the final rule covers a tiny fraction of the market the MFN approach was meant to touch. The savings collapse matches independent estimates. Transparency is missing entirely — the public cannot know which firms are facing the new requirements and which are not.

This rule shows how administrative discretion can shrink a policy’s reach well below its stated goals. When agencies exempt whole categories of firms without naming them, the public loses sight of who is covered and who is not. The administration’s own estimates show the savings collapsed. The question now is whether that collapse will hold, and whether the public will ever learn which four companies the rule actually affects.

See the a run of 32 images at STAT.

drug pricing · Global rule · healthcare policy · Medicare · Trump administration